The COMPARATIVE PHARMACOLOGICAL EVALUATION OF DOLICHOS ACIPHYLLUS EXTRACT AND ITS LIPID-BASED FORMULATION IN EXPERIMENTAL HYPERLIPIDEMIA

Q: What are the key findings of this study?

Dolichos aciphyllus extract and its nanostructured lipid carrier (400 mg/kg) significantly reduced serum lipids and inhibited HMG-CoA reductase by 77.12% and 86.81%.

Q: What is the clinical evidence from this study?

Population: High-fat diet (HFD)-induced experimental hyperlipidemia (n=30). Intervention: Dolichos aciphyllus extract (DAE) and DAE-loaded nanostructured lipid carriers (DAENLCs) vs. Normal diet control, high-fat diet negative control (vehicle), and positive control (atorvastatin 10 mg/kg). Primary outcome: Serum lipid parameters (total cholesterol, TG, LDL, VLDL, HDL) and in vitro HMG-CoA reductase inhibition (p=<0.0001).

Q: What does this research mean for the field?

Dolichos aciphyllus extract and its nanostructured lipid carrier formulation significantly reduce serum lipid levels and oxidative stress in hyperlipidemic rats, while markedly inhibiting HMG-CoA reductase. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To analyze the antihyperlipidemic and antioxidant efficacy of Dolichos aciphyllus extract (DAE) and its nanostructured lipid carrier formulation (DAENLC) against high-fat diet-induced hyperlipidemia.

Moumita Barman; Praveen Kumar Gaur; Dheeraj Nagpal

doi:10.22159/ajpcr.2026v19i11.60703

November 7, 2026Asian Journal of Pharmaceutical and Clinical ResearchOpen Access

The COMPARATIVE PHARMACOLOGICAL EVALUATION OF DOLICHOS ACIPHYLLUS EXTRACT AND ITS LIPID-BASED FORMULATION IN EXPERIMENTAL HYPERLIPIDEMIA

View Full Paper

Ask AI

Bookmark

Share

Key result

Nanostructured Dolichos aciphyllus extract lowers lipids and inhibits HMG-CoA reductase by ~87%.

P<0.0001
n=30

Why the study?

The antihyperlipidemic and antioxidant efficacy of Dolichos aciphyllus extract and its nanostructured lipid carrier formulation against high-fat diet-induced hyperlipidemia required comparative pharmacological evaluation.

Does Dolichos aciphyllus extract and its nanostructured lipid carrier formulation improve serum lipid parameters and oxidative stress in rats with high-fat diet-induced hyperlipidemia?

Key Points

To analyze the antihyperlipidemic and antioxidant efficacy of Dolichos aciphyllus extract (DAE) and its nanostructured lipid carrier formulation (DAENLC) against high-fat diet-induced hyperlipidemia.
Evaluated in vitro HMG-CoA reductase inhibition of DAE and DAENLC alongside standard atorvastatin.
Assigned Wistar albino rats to 5 groups (N=6 per group) fed a normal or high-fat diet (HFD) and treated orally with vehicle, atorvastatin (10 mg/kg), DAE (400 mg/kg), or DAENLC (400 mg/kg).
Assessed serum lipid panels, oxidative stress markers (MDA, GSH, SOD, CAT), liver transaminases (AST, ALT), and hepatic histology.
Ethanolic DAE and DAENLC inhibited in vitro HMG-CoA reductase by 77.12% and 86.81%, respectively, compared with 90.56% for atorvastatin.
Treatment with 400 mg/kg DAE and DAENLC significantly decreased body weight gain (p<0.05) and reduced serum total cholesterol, TG, LDL, VLDL, and atherogenic index while increasing HDL versus HFD controls.
DAENLC notably reduced AST, ALT, and MDA levels while restoring GSH, SOD, and CAT activities and providing greater hepatic tissue protection than pure DAE.

Structured PICO

Does Dolichos aciphyllus extract and its nanostructured lipid carrier formulation improve serum lipid parameters and oxidative stress in rats with high-fat diet-induced hyperlipidemia?

P

Population

30 adult female Wistar albino rats with high-fat diet-induced hyperlipidemia followed for 90 days across 5 experimental groups.

I

Intervention

Dolichos aciphyllus extract (DAE) 400 mg/kg or DAE-loaded nanostructured lipid carriers (DAENLCs) 400 mg/kg administered orally once daily along with high-fat diet for 90 days.

C

Comparator

Control group receiving normal diet + 0.9% NaCl vehicle (n=6), negative control receiving high-fat diet + vehicle (n=6), and positive control receiving high-fat diet + atorvastatin 10 mg/kg (n=6).

O

Outcome

Serum lipid profile (total cholesterol, triglycerides, HDL, LDL, VLDL, and atherogenic index) at 90 days and in vitro HMG-CoA reductase inhibition.surrogate

Main Result

Absolute Event Rate: 86.81% vs 90.56%

p-value: p=<0.0001

Formulating Dolichos aciphyllus extract into nanostructured lipid carriers enhanced its lipid-lowering, antioxidant, and hepatoprotective effects in a rat model of diet-induced hyperlipidemia.

Limitations

Preclinical animal model (female Wistar albino rats) limiting direct clinical generalizability
Complete analytical method validation parameters (LOD, LOQ, precision, accuracy) for HPLC quercetin estimation were not established
Detailed formulation characterization (morphology, DSC, in vitro drug release, stability) was not performed
Histopathological examination was not performed on organs collected at the end of the acute oral toxicity observation period
Preclinical animal study in female Wistar albino rats
Complete analytical method validation parameters (limit of detection, limit of quantitation, intra-day/inter-day precision, accuracy/recovery) were not established for the HPLC quercetin assay
Detailed formulation characterization (morphology, differential scanning calorimetry, in vitro drug release, stability) was beyond the study scope
Histopathological examination was not performed on organs collected at the end of the 14-day acute oral toxicity observation period

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Supports preclinical development of Dolichos aciphyllus nanostructured lipid carriers; leaves open translation to human hyperlipidemia therapy.

Abstract

Objective: The major aim of the current research work was to analyze the antihyperlipidemic and antioxidant efficacy of Dolichos aciphyllus extract (DAE) and its prepared lipid-based formulation (Dolichos aciphyllus extract-loaded nanostructured lipid carriers [DAENLCs]) against the high-fat diet (HFD)-induced hyperlipidemic rats. Methods: Antihyperlipidemic efficacy of DAE was analyzed initially by in vitro 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibition. HFD was used to induce hyperlipidemia in Wistar albino rats, followed by oral administration of DAE (400 mg/kg) and DAENLCs (400 mg/kg). The serum lipid parameters, such as cholesterol, triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), were analyzed. Oxidative stress markers were determined by estimating malondialdehyde (MDA), reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT). Liver function markers, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), were also assessed, along with histopathological changes in liver and adipose tissue, together with phytochemical screening and high-performance liquid chromatography (HPLC) fingerprinting for identifying the major phytochemical constituents. Results: The recent study showed that DAE and DAENLCs have marked in vitro HMG-CoA reductase inhibitor activity, followed by the lipid-based formulation showing greater inhibition than the pure extract. Treatment with a high dose of DAE and DAENLCs in HFD-induced hyperlipidemic rats showed a considerable reduction in the levels of serum total cholesterol, TG, LDL, VLDL, and atherogenic index while increasing the HDL levels when compared with the control group. The levels of AST and ALT, along with MDA levels, were also reduced considerably in the treatment groups when compared to the standard drug atorvastatin, while restoring the GSH, SOD, and CAT activities. The histopathological results showed improvement in the liver structure and morphology of adipose tissue in the treatment groups, where DAENLC demonstrated better protection of the tissue than DAE. The presence of quercetin in DAE was confirmed by the preliminary HPLC fingerprinting analysis by comparison with the standard quercetin. Conclusion: DAE showed potential antihyperlipidemia and antioxidant efficacy in hyperlipidemic rats, which was further increased when formulated in a lipid-based formulation. DAENLC showed improvement in lipid metabolism, oxidative stress, liver function, and alterations in liver architecture when compared with the pure extract. Thus, DAENLCs showed an enhanced pharmacological activity of Dolichos aciphyllus, which makes DAENLC a promising phyto-pharmaceutical strategy for treating hyperlipidemia and other metabolic disorders.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Barman et al. (2026) studied High-fat diet (HFD)-induced experimental hyperlipidemia (n=30). Dolichos aciphyllus extract (DAE) and DAE-loaded nanostructured lipid carriers (DAENLCs) vs. Normal diet control, high-fat diet negative control (vehicle), and positive control (atorvastatin 10 mg/kg) was evaluated on Serum lipid parameters (total cholesterol, TG, LDL, VLDL, HDL) and in vitro HMG-CoA reductase inhibition (p=<0.0001). Dolichos aciphyllus extract and its nanostructured lipid carrier (400 mg/kg) significantly reduced serum lipids and inhibited HMG-CoA reductase by 77.12% and 86.81%.

synapsesocial.com/papers/6af0e999de503f3774140a85 https://doi.org/10.22159/ajpcr.2026v19i11.60703

View Full Paper

Ask AI

Bookmark

Share

The COMPARATIVE PHARMACOLOGICAL EVALUATION OF DOLICHOS ACIPHYLLUS EXTRACT AND ITS LIPID-BASED FORMULATION IN EXPERIMENTAL HYPERLIPIDEMIA

Key Points

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

The COMPARATIVE PHARMACOLOGICAL EVALUATION OF DOLICHOS ACIPHYLLUS EXTRACT AND ITS LIPID-BASED FORMULATION IN EXPERIMENTAL HYPERLIPIDEMIA

Key Points

Structured PICO

Main Result

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading